• Telomir Pharmaceuticals completed acquisition of TELI Pharmaceuticals on April 22, 2026, issuing 34,389,710 restricted common shares in an unregistered transaction.
• Shares were issued to TELI former shareholders under Securities Act Section 4(a)(2) exemption, relying on Rule 506.
• Bayshore Trust contributed USD 1 million at closing as condition to transaction.
• Commitment agreement gives Bayshore option to invest up to USD 4 million tied to Telomir-1 development milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-018867), on April 24, 2026, and is solely responsible for the information contained therein.